MX370785B - Composiciones farmacéuticas que contienen fumarato de dimetilo. - Google Patents
Composiciones farmacéuticas que contienen fumarato de dimetilo.Info
- Publication number
- MX370785B MX370785B MX2014009469A MX2014009469A MX370785B MX 370785 B MX370785 B MX 370785B MX 2014009469 A MX2014009469 A MX 2014009469A MX 2014009469 A MX2014009469 A MX 2014009469A MX 370785 B MX370785 B MX 370785B
- Authority
- MX
- Mexico
- Prior art keywords
- dimethyl fumarate
- compositions containing
- compositions
- pharmaceutical compositions
- containing dimethyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Se proporcionan en la presente composiciones que contienen compuestos, o sales farmacéuticamente aceptables, que se metabolizan en fumarato de monometilo con ciertos parámetros farmacocinéticos y métodos para tratar, profilaxis, o mejora de enfermedades neurodegenerativas que incluyen esclerosis múltiple utilizando tales composiciones en un sujeto, en donde si las composiciones contienen fumarato de dimetilo, la cantidad total de fumarato de dimetilo en las composiciones oscila de alrededor de 43% p/p a alrededor de 95% p/p.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261596202P | 2012-02-07 | 2012-02-07 | |
| US201261625621P | 2012-04-17 | 2012-04-17 | |
| US201261723048P | 2012-11-06 | 2012-11-06 | |
| PCT/US2013/024946 WO2013119677A1 (en) | 2012-02-07 | 2013-02-06 | Pharmaceutical compositions containing dimethyl fumarate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014009469A MX2014009469A (es) | 2014-09-22 |
| MX370785B true MX370785B (es) | 2020-01-06 |
Family
ID=48947963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014009469A MX370785B (es) | 2012-02-07 | 2013-02-06 | Composiciones farmacéuticas que contienen fumarato de dimetilo. |
Country Status (24)
| Country | Link |
|---|---|
| US (7) | US20130216615A1 (es) |
| EP (1) | EP2811994A4 (es) |
| JP (4) | JP6189333B2 (es) |
| KR (1) | KR102105217B1 (es) |
| CN (5) | CN114146079A (es) |
| AR (1) | AR089931A1 (es) |
| AU (6) | AU2013203445C1 (es) |
| BR (1) | BR112014019462B1 (es) |
| CA (1) | CA2862885C (es) |
| CL (1) | CL2014002077A1 (es) |
| CO (1) | CO7141407A2 (es) |
| EA (1) | EA038152B1 (es) |
| EC (1) | ECSP14014870A (es) |
| HK (1) | HK1202261A1 (es) |
| IL (2) | IL233833B (es) |
| MX (1) | MX370785B (es) |
| NI (1) | NI201400086A (es) |
| NZ (1) | NZ627980A (es) |
| PE (1) | PE20150092A1 (es) |
| PH (1) | PH12014501750A1 (es) |
| SG (1) | SG11201404705YA (es) |
| TW (4) | TW202102205A (es) |
| WO (1) | WO2013119677A1 (es) |
| ZA (1) | ZA201405511B (es) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0410805A (pt) | 2003-09-09 | 2006-06-27 | Fumapharm Ag | uso de derivados do ácido fumárico para tratamento da insuficiência cardìaca e asma |
| DE14172398T1 (de) | 2004-10-08 | 2015-01-08 | Forward Pharma A/S | Gesteuerte Freisetzung von pharmazeutischen Zusammensetzungen mit Fumarinsäureester |
| EP3135282A1 (en) * | 2007-02-08 | 2017-03-01 | Biogen MA Inc. | Neuroprotection in demyelinating diseases |
| DK2334378T3 (da) | 2008-08-19 | 2014-07-07 | Xenoport Inc | Prodrugs af methylhydrogenfumarat, farmaceutiske sammensætninger deraf og fremgangsmåder til anvendelse |
| HUE036085T2 (hu) | 2011-06-08 | 2018-06-28 | Biogen Ma Inc | Nagy tisztaságú és kristályos dimetil-fumarát elõállítására szolgáló eljárás |
| CN114146079A (zh) * | 2012-02-07 | 2022-03-08 | 比奥根玛公司 | 含有富马酸二甲酯的药物组合物 |
| AU2013305684B2 (en) | 2012-08-22 | 2016-11-24 | Xenoport, Inc. | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof |
| US10945984B2 (en) | 2012-08-22 | 2021-03-16 | Arbor Pharmaceuticals, Llc | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects |
| US20140179779A1 (en) | 2012-12-21 | 2014-06-26 | Biogen Idec Ma Inc. | Deuterium Substituted Fumarate Derivatives |
| HUE040044T2 (hu) | 2013-03-14 | 2019-02-28 | Alkermes Pharma Ireland Ltd | Fumarátok prodrugjai, és azok alkalmazása különbözõ betegségek kezelésében |
| US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
| WO2014143146A1 (en) * | 2013-03-15 | 2014-09-18 | Xenoport, Inc. | Methods of administering monomethyl fumarate |
| WO2014160633A1 (en) | 2013-03-24 | 2014-10-02 | Xenoport, Inc. | Pharmaceutical compositions of dimethyl fumarate |
| US9302977B2 (en) | 2013-06-07 | 2016-04-05 | Xenoport, Inc. | Method of making monomethyl fumarate |
| WO2014205392A1 (en) | 2013-06-21 | 2014-12-24 | Xenoport, Inc. | Cocrystals of dimethyl fumarate |
| TW201516020A (zh) | 2013-09-06 | 2015-05-01 | Xenoport Inc | （ｎ，ｎ－二乙基胺甲醯基）甲基（２ｅ）丁－２－烯－１，４－二酸甲酯之晶形、合成方法及用途 |
| PT3079666T (pt) | 2013-12-12 | 2021-02-18 | Almirall Sa | Composições farmacêuticas que contêm fumarato de dimetilo |
| US10172794B2 (en) | 2013-12-13 | 2019-01-08 | Biogen Ma Inc. | Controlled release dosage form for once daily administration of dimethyl fumarate |
| US9604922B2 (en) | 2014-02-24 | 2017-03-28 | Alkermes Pharma Ireland Limited | Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases |
| US9636318B2 (en) | 2015-08-31 | 2017-05-02 | Banner Life Sciences Llc | Fumarate ester dosage forms |
| US9326947B1 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
| US10098863B2 (en) | 2014-02-28 | 2018-10-16 | Banner Life Sciences Llc | Fumarate esters |
| DK3110408T3 (en) | 2014-02-28 | 2019-04-29 | Banner Life Sciences Llc | ENTERY SOFT CAPS OF CONTROLLED RELEASE FUMAR TESTERS |
| EP3116536A1 (en) | 2014-03-14 | 2017-01-18 | Biogen MA Inc. | Dimethyl fumarate and vaccination regimens |
| US9999672B2 (en) | 2014-03-24 | 2018-06-19 | Xenoport, Inc. | Pharmaceutical compositions of fumaric acid esters |
| WO2016057133A1 (en) * | 2014-10-08 | 2016-04-14 | Banner Life Sciences Llc | Controlled release enteric soft capsules of fumarate esters |
| EP3212626B1 (en) * | 2014-10-27 | 2018-11-07 | Cellix Bio Private Limited | Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis |
| MA40985A (fr) | 2014-11-17 | 2017-09-26 | Biogen Ma Inc | Méthodes de traitement de la sclérose en plaques |
| MA40982A (fr) * | 2014-11-19 | 2017-09-26 | Biogen Ma Inc | Formulation de bille pharmaceutique comprenant du fumarate de diméthyle |
| MA40990A (fr) * | 2014-11-19 | 2017-09-26 | Biogen Ma Inc | Formulations de matrice pharmaceutique comprenant du fumarate de diméthyle |
| CN104490849A (zh) * | 2014-11-24 | 2015-04-08 | 广东东阳光药业有限公司 | 一种高密度的富马酸二甲酯肠溶颗粒及其制备方法 |
| MA41139A (fr) | 2014-12-11 | 2017-10-17 | Actelion Pharmaceuticals Ltd | Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1 |
| CN107847451A (zh) * | 2015-02-02 | 2018-03-27 | 英仕柏集团有限责任公司 | 稳定的富马酸二烷基酯组合物 |
| SG11201705124QA (en) | 2015-02-08 | 2017-07-28 | Alkermes Pharma Ireland Ltd | Monomethylfumarate prodrug compositions |
| AU2016231883B2 (en) * | 2015-03-17 | 2019-03-07 | Hetero Labs Limited | Pharmaceutical compositions of dimethyl fumarate |
| MA41785A (fr) | 2015-03-20 | 2018-01-23 | Biogen Ma Inc | Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques |
| AU2016273068A1 (en) | 2015-06-01 | 2017-12-21 | Sun Pharmaceutical Industries Ltd. | Pharmaceutical compositions of dimethyl fumarate |
| EP3310341A1 (en) | 2015-06-17 | 2018-04-25 | Biogen MA Inc. | Dimethyl fumarate particles and pharmaceutical compositions thereof |
| WO2017056107A1 (en) | 2015-09-28 | 2017-04-06 | Natco Pharma Ltd | Pharmaceutical compositions of dimethyl fumarate |
| BR112018008835A8 (pt) * | 2015-10-28 | 2019-02-26 | Sun Pharmaceutical Ind Ltd | composição farmacêutica oral, composição farmacêutica de liberação pulsátil oral, método para tratar uma condição de doença que requer terapia com fumarato de dimetila e método para tratar esclerose múltipla |
| EA201800403A1 (ru) | 2015-12-31 | 2018-12-28 | Заклады Фармацеутицне Польфарма С.А. | Способ получения покрытого кишечнорастворимой оболочкой гранулята, содержащего диметилфумарат |
| WO2017129370A1 (en) * | 2016-01-28 | 2017-08-03 | Zaklady Farmaceutyczne Polpharma S.A. | Process for preparation of a granulate comprising dimethyl fumarate |
| CA3013472A1 (en) * | 2016-02-11 | 2017-08-17 | Biogen Ma Inc. | Pharmaceutical bead formulations comprising dimethyl fumarate |
| WO2017145036A1 (en) * | 2016-02-25 | 2017-08-31 | Aurobindo Pharma Ltd | Pharmaceutical compositions comprising dimethyl fumarate |
| TR201616998A1 (en) | 2016-11-23 | 2018-06-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | DELAYED RELEASE DOSING FORMS WITH DIMETHYL FUMARATE |
| EP3595640A4 (en) * | 2017-03-17 | 2020-09-23 | Vitalis LLC | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS |
| EP3641736A1 (en) | 2017-06-23 | 2020-04-29 | Almirall, S.A. | Pharmaceutical compositions comprising dimethyl fumarate |
| US20210251910A1 (en) * | 2018-09-10 | 2021-08-19 | Vitalis Llc | Fumaric acid compositions with increased bioavailability and reduced side effects |
| US11446055B1 (en) | 2018-10-18 | 2022-09-20 | Lumoptik, Inc. | Light assisted needle placement system and method |
| TR201818293A2 (tr) | 2018-11-30 | 2020-06-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Di̇meti̇l fumarat i̇çeren geci̇kmeli̇ salim sağlayan kapsül |
| US11903918B2 (en) | 2020-01-10 | 2024-02-20 | Banner Life Sciences Llc | Fumarate ester dosage forms with enhanced gastrointestinal tolerability |
| EP4117785A4 (en) * | 2020-03-13 | 2024-04-17 | Marc J. Simard | METHODS OF TREATMENT OF MULTIPLE SCLEROSIS |
| CA3182369A1 (en) | 2020-05-06 | 2021-07-22 | Imcyse Sa | Combination treatment for fumarate-related diseases |
| BR112023025435A2 (pt) * | 2021-06-04 | 2024-02-27 | Zim Laboratories Ltd | Composições de liberação retardada de fumarato de dimetila |
| US20240010618A1 (en) | 2021-12-23 | 2024-01-11 | Glenmark Lofe Science Limited | Process for the preparation of brivaracetam |
| CN115590831A (zh) * | 2022-10-26 | 2023-01-13 | 力品药业（厦门）股份有限公司（Cn） | 一种富马酸二甲酯缓释微片及其制备方法 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1153927A (en) | 1966-08-25 | 1969-06-04 | Wilhelm Hoerrmann | Medicinal Composition Suitable For Treating Diseases Of The Retina |
| US5424332A (en) | 1987-10-19 | 1995-06-13 | Speiser; Peter P. | Pharmaceutical composition and process for the production thereof |
| US4959389A (en) | 1987-10-19 | 1990-09-25 | Speiser Peter P | Pharmaceutical preparation for the treatment of psoriatic arthritis |
| US5484610A (en) | 1991-01-02 | 1996-01-16 | Macromed, Inc. | pH and temperature sensitive terpolymers for oral drug delivery |
| DE19721099C2 (de) | 1997-05-20 | 1999-12-02 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten |
| FI109088B (fi) * | 1997-09-19 | 2002-05-31 | Leiras Oy | Tabletti ja menetelmä sen valmistamiseksi |
| DE19814358C2 (de) * | 1998-03-31 | 2002-01-17 | Fumapharm Ag Muri | Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn |
| DE19839566C2 (de) | 1998-08-31 | 2002-01-17 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten in der Transplantationsmedizin |
| DE19848260C2 (de) | 1998-10-20 | 2002-01-17 | Fumapharm Ag Muri | Fumarsäure-Mikrotabletten |
| DE19853487A1 (de) * | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| US6537584B1 (en) | 1999-11-12 | 2003-03-25 | Macromed, Inc. | Polymer blends that swell in an acidic environment and deswell in a basic environment |
| DE10000577A1 (de) | 2000-01-10 | 2001-07-26 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten |
| US6399101B1 (en) | 2000-03-30 | 2002-06-04 | Mova Pharmaceutical Corp. | Stable thyroid hormone preparations and method of making same |
| US7217431B2 (en) | 2001-07-06 | 2007-05-15 | Lifecycle Pharma A/S | Controlled agglomeration |
| KR100540035B1 (ko) * | 2002-02-01 | 2005-12-29 | 주식회사 태평양 | 다단계 경구 약물 방출 제어 시스템 |
| DE10214031A1 (de) | 2002-03-27 | 2004-02-19 | Pharmatech Gmbh | Verfahren zur Herstellung und Anwendung von Mikro- und Nanoteilchen durch aufbauende Mikronisation |
| BRPI0408323A (pt) * | 2003-03-14 | 2006-03-07 | Nirmal Mulye | processo para a preparação de compimidos de liberação prolongada |
| DE10360869A1 (de) * | 2003-09-09 | 2005-04-07 | Fumapharm Ag | Verwendung von Fumarsäurederivaten zur Therapie der Herzinsuffizienz, der Hyperkeratose und von Asthma |
| BRPI0410805A (pt) * | 2003-09-09 | 2006-06-27 | Fumapharm Ag | uso de derivados do ácido fumárico para tratamento da insuficiência cardìaca e asma |
| CN101056624A (zh) * | 2004-10-08 | 2007-10-17 | Adi技术制药股份公司 | 包含富马酸酯的控释药物组合物 |
| DE14172398T1 (de) * | 2004-10-08 | 2015-01-08 | Forward Pharma A/S | Gesteuerte Freisetzung von pharmazeutischen Zusammensetzungen mit Fumarinsäureester |
| US20080227847A1 (en) * | 2005-07-07 | 2008-09-18 | Aditech Pharma Ab | Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use |
| WO2007042035A2 (en) | 2005-10-07 | 2007-04-19 | Aditech Pharma Ab | Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders |
| WO2007042034A1 (en) | 2005-10-07 | 2007-04-19 | Aditech Pharma Ab | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
| WO2007079082A2 (en) * | 2005-12-30 | 2007-07-12 | Advancis Pharmaceutical Corporation | Gastric release pulse system for drug delivery |
| CA2685261A1 (en) * | 2007-04-25 | 2008-11-06 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical excipient complex |
| CA2709709A1 (en) * | 2007-12-21 | 2009-07-09 | Mcneil-Ppc, Inc. | Manufacture of tablet |
| AU2009249600A1 (en) * | 2008-05-20 | 2009-11-26 | Cerenis Therapeutics Holding S.A. | Niacin and NSAID for combination therapy |
| DK2334378T3 (da) * | 2008-08-19 | 2014-07-07 | Xenoport Inc | Prodrugs af methylhydrogenfumarat, farmaceutiske sammensætninger deraf og fremgangsmåder til anvendelse |
| WO2010079221A1 (en) | 2009-01-09 | 2010-07-15 | Forward Pharma A/S | Pharmaceutical composition comprising one or more fumaric acid esters |
| PT2564839T (pt) | 2009-01-09 | 2016-07-14 | Forward Pharma As | Formulação farmacêutica compreendendo um ou mais ésteres de ácido fumárico numa matriz de erosão |
| EP3466420A1 (en) | 2009-04-29 | 2019-04-10 | Biogen MA Inc. | Dimethyl fumarate for the treatment of friedreich ataxia |
| US20100285164A1 (en) | 2009-05-11 | 2010-11-11 | Jrs Pharma | Orally Disintegrating Excipient |
| DK2533634T3 (en) * | 2010-02-12 | 2016-01-25 | Biogen Ma Inc | NEURO PROTECTIVE demyelinating diseases |
| CN114146079A (zh) * | 2012-02-07 | 2022-03-08 | 比奥根玛公司 | 含有富马酸二甲酯的药物组合物 |
-
2013
- 2013-02-06 CN CN202111171982.7A patent/CN114146079A/zh active Pending
- 2013-02-06 EP EP13746306.3A patent/EP2811994A4/en active Pending
- 2013-02-06 CA CA2862885A patent/CA2862885C/en active Active
- 2013-02-06 CN CN202111173089.8A patent/CN114146081A/zh active Pending
- 2013-02-06 NZ NZ627980A patent/NZ627980A/en unknown
- 2013-02-06 AU AU2013203445A patent/AU2013203445C1/en active Active
- 2013-02-06 KR KR1020147024886A patent/KR102105217B1/ko active IP Right Grant
- 2013-02-06 EA EA201491484A patent/EA038152B1/ru unknown
- 2013-02-06 PE PE2014001232A patent/PE20150092A1/es not_active Application Discontinuation
- 2013-02-06 JP JP2014555852A patent/JP6189333B2/ja not_active Expired - Fee Related
- 2013-02-06 CN CN202110490355.3A patent/CN113244185A/zh active Pending
- 2013-02-06 MX MX2014009469A patent/MX370785B/es active IP Right Grant
- 2013-02-06 BR BR112014019462-9A patent/BR112014019462B1/pt active IP Right Grant
- 2013-02-06 SG SG11201404705YA patent/SG11201404705YA/en unknown
- 2013-02-06 CN CN202111172018.6A patent/CN114146080A/zh active Pending
- 2013-02-06 US US13/760,916 patent/US20130216615A1/en not_active Abandoned
- 2013-02-06 CN CN201380018792.9A patent/CN104220061A/zh active Pending
- 2013-02-06 WO PCT/US2013/024946 patent/WO2013119677A1/en active Application Filing
- 2013-02-07 TW TW109108318A patent/TW202102205A/zh unknown
- 2013-02-07 TW TW106127330A patent/TWI697338B/zh active
- 2013-02-07 AR ARP130100385A patent/AR089931A1/es not_active Application Discontinuation
- 2013-02-07 TW TW102104904A patent/TWI676475B/zh active
- 2013-02-07 TW TW110139187A patent/TW202231268A/zh unknown
- 2013-03-14 US US13/827,228 patent/US20130295169A1/en not_active Abandoned
- 2013-04-12 AU AU2013204286A patent/AU2013204286B2/en active Active
-
2014
- 2014-07-25 ZA ZA2014/05511A patent/ZA201405511B/en unknown
- 2014-07-28 IL IL233833A patent/IL233833B/en unknown
- 2014-08-04 PH PH12014501750A patent/PH12014501750A1/en unknown
- 2014-08-06 CL CL2014002077A patent/CL2014002077A1/es unknown
- 2014-08-06 NI NI201400086A patent/NI201400086A/es unknown
- 2014-08-20 EC ECIEPI201414870A patent/ECSP14014870A/es unknown
- 2014-09-05 CO CO14196527A patent/CO7141407A2/es unknown
-
2015
- 2015-03-18 HK HK15102805.4A patent/HK1202261A1/xx unknown
- 2015-04-06 US US14/679,716 patent/US20150209318A1/en not_active Abandoned
-
2017
- 2017-01-20 AU AU2017200394A patent/AU2017200394B2/en active Active
- 2017-07-28 AU AU2017208367A patent/AU2017208367A1/en not_active Abandoned
- 2017-08-02 JP JP2017149548A patent/JP6430598B2/ja active Active
-
2018
- 2018-03-02 US US15/910,745 patent/US20180185319A1/en not_active Abandoned
- 2018-05-24 US US15/988,568 patent/US20180263946A1/en not_active Abandoned
- 2018-10-31 JP JP2018204599A patent/JP2019059732A/ja active Pending
- 2018-11-09 AU AU2018260937A patent/AU2018260937B2/en active Active
-
2019
- 2019-08-05 US US16/532,155 patent/US20190358190A1/en not_active Abandoned
-
2020
- 2020-03-23 US US16/826,938 patent/US20200222354A1/en not_active Abandoned
- 2020-09-28 AU AU2020244395A patent/AU2020244395B2/en not_active Expired - Fee Related
-
2021
- 2021-11-12 JP JP2021184462A patent/JP2022024048A/ja active Pending
-
2022
- 2022-02-06 IL IL290378A patent/IL290378B2/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX370785B (es) | Composiciones farmacéuticas que contienen fumarato de dimetilo. | |
| PH12018501410A1 (en) | Therapeutically active compounds and their method of use | |
| WO2014096425A3 (en) | Prodrugs of monomethyl fumarate (mmf) | |
| MY160249A (en) | Fatty acid fumarate derivatives and their uses | |
| MY183582A (en) | Deuterated cftr potentiators | |
| MX349159B (es) | Derivados deuterados de ivacaftor. | |
| MX350432B (es) | Compuestos terapeuticamente activos y sus metodos de empleo. | |
| PH12014501967A1 (en) | Benzodioxanes in combination with other actives for inhibiting leukotriene production | |
| MX349224B (es) | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa. | |
| MX2015012741A (es) | Palbociclib deuterado. | |
| EA032271B9 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний | |
| IN2015DN01023A (es) | ||
| HK1192726A1 (en) | 1,2,4-thiadiazol-5-ylpiperazine derivatives useful in the treatment of neurodegenerative diseases 124--5- | |
| MX2015008187A (es) | Inhibidores de alk deuterados. | |
| WO2013087654A3 (en) | Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation | |
| NZ707773A (en) | Methods of treating liver diseases | |
| IN2014DN00123A (es) | ||
| MX2015013151A (es) | Métodos de tratamiento de disquinesia y trastornos relacionados. | |
| MX2013012967A (es) | Composicion de miel con l-alanil-l-glutamina. | |
| WO2013033602A3 (en) | Fatty acid amides, compositions and methods of use | |
| TN2014000321A1 (en) | Pharmaceutical compositions containing dimethyl fumarate | |
| EP2789334A4 (en) | PHARMACEUTICAL COMPOSITION COMPRISING DIAMINODIPHENYLSULFONE OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH MUSCLE ATROPHY | |
| IN2013MU03428A (es) | ||
| MX2014001862A (es) | 5-cicloalquil-o 5-heterociclil-nicotinamidas. | |
| WO2013158698A3 (en) | Method treating scleroderma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HC | Change of company name or juridical status |
Owner name: SHIRE HUMAN GENETIC THERAPIES, INC. Owner name: W. R. GRACE & CO.-CONN |
|
| FG | Grant or registration |